Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VEGF CRISPR/Cas9 KO Plasmid (m): sc-423665
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VEGF CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the VEGF genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VEGF Antibody (C-1): sc-7269
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF CRISPR/Cas9 KO Plasmid (m) | sc-423665 | 20 µg | $397.00 |
Overview
Vegfa encodes vascular endothelial growth factor (VEGF), a secreted cytokine that drives endothelial cell proliferation, migration, and survival during embryonic vasculogenesis and postnatal angiogenesis. VEGF signaling primarily engages VEGFR2 to activate PI3K–AKT, MAPK/ERK, PLCγ–PKC, and nitric oxide pathways, coordinating vascular permeability and tissue perfusion responses to hypoxia via HIF-dependent regulation. In mouse models, altered Vegfa dosage impacts vessel patterning, wound repair, and inflammatory tissue remodeling. Dysregulated VEGF signaling is broadly studied in contexts such as tumor-associated angiogenesis, retinal neovascularization, and ischemia-related vascular adaptation without implying therapeutic outcomes.
VEGF CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Vegfa gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Vegfa together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Vegfa open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish VEGF protein expression.
This CRISPR knockout system enables efficient generation of Vegfa-deficient cell models for investigation of VEGF signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Vegfa exon(s) critical for VEGF function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Vegfa genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by VEGF CRISPR/Cas9 KO Plasmid (m) and VEGF CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Vegfa locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by VEGF HDR Plasmid (m) and VEGF HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Vegfa homology arms to support homology-directed repair at defined Vegfa target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.